These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
298 related items for PubMed ID: 8254956
1. [Clinical usefulness of tumor markers in breast cancer]. Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F. Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [Abstract] [Full Text] [Related]
2. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer]. Kaneko Y, Imoto S, Kasakura S. Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542 [Abstract] [Full Text] [Related]
3. [Evaluation of tumor marker CA15-3 in breast cancer]. Kikuchi K, Uematsu Y, Takada Y, Kurihara E, Suito T, Fujisaki M, Takahashi R, Tamura T. Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052 [Abstract] [Full Text] [Related]
4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Samy N, Ragab HM, El Maksoud NA, Shaalan M. Cancer Biomark; 2010 Nov; 6(2):63-72. PubMed ID: 20571232 [Abstract] [Full Text] [Related]
5. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H. Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359 [Abstract] [Full Text] [Related]
6. [Tumor markers in breast cancer]. Harada Y, Ohuchi N, Ishida T, Ohnuki K. Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135 [Abstract] [Full Text] [Related]
7. [Clinical evaluation of tumor markers in breast cancer patients]. Ito T, Tanaka S, Ban K, Sakai N, Oshita H, Oiwa T, Kanno A, Kashizuka T. Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907 [Abstract] [Full Text] [Related]
8. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Gion M, Peloso L, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M, Cappelli G. Cancer J; 2001 Oct; 7(3):181-90. PubMed ID: 11419026 [Abstract] [Full Text] [Related]
9. [Tumor markers in the diagnosis and prognosis of breast cancer]. Seliuzhitskiĭ IV, Skvortsov SV, Lytsar BN, Khomenko LP. Klin Med (Mosk); 1993 Oct; 71(2):25-7. PubMed ID: 8046917 [Abstract] [Full Text] [Related]
12. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Cancer Res; 1988 Jul 15; 48(14):4107-12. PubMed ID: 3164256 [Abstract] [Full Text] [Related]
15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K, Kato Y, Hirakawa K. Clin Cancer Res; 2000 Oct 15; 6(10):4069-72. PubMed ID: 11051258 [Abstract] [Full Text] [Related]
19. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Fujino N, Haga Y, Sakamoto K, Egami H, Kimura M, Nishimura R, Akagi M. Jpn J Clin Oncol; 1986 Dec 15; 16(4):335-46. PubMed ID: 3467106 [Abstract] [Full Text] [Related]